NeoPharm CO., LTD. (KOSDAQ:092730)
South Korea
· Delayed Price · Currency is KRW 13,460
+340 (2.59%)
Apr 1, 2025, 3:30 PM KST
NeoPharm CO., LTD. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 119,014 | 97,105 | 85,033 | 87,931 | 81,625 | Upgrade
|
| Other Revenue | - | - | -0 | - | - | Upgrade
|
| Revenue | 119,014 | 97,105 | 85,033 | 87,931 | 81,625 | Upgrade
|
| Revenue Growth (YoY) | 22.56% | 14.20% | -3.29% | 7.72% | -1.94% | Upgrade
|
| Cost of Revenue | 44,987 | 31,720 | 26,653 | 25,544 | 22,984 | Upgrade
|
| Gross Profit | 74,027 | 65,385 | 58,380 | 62,386 | 58,642 | Upgrade
|
| Selling, General & Admin | 44,259 | 36,276 | 32,984 | 36,022 | 32,991 | Upgrade
|
| Research & Development | 3,407 | 2,647 | 2,854 | 2,935 | 2,802 | Upgrade
|
| Operating Expenses | 49,374 | 40,078 | 36,941 | 39,955 | 36,740 | Upgrade
|
| Operating Income | 24,653 | 25,307 | 21,439 | 22,431 | 21,902 | Upgrade
|
| Interest Expense | -40.78 | -21.32 | -8.84 | -38.46 | -56.37 | Upgrade
|
| Interest & Investment Income | 4,155 | 4,588 | 2,077 | 1,177 | 1,366 | Upgrade
|
| Currency Exchange Gain (Loss) | 2,006 | -117.74 | 205.38 | 662.9 | -126.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -795.4 | -362.95 | -376.73 | -430.38 | -138.91 | Upgrade
|
| EBT Excluding Unusual Items | 29,978 | 29,393 | 23,335 | 23,801 | 22,947 | Upgrade
|
| Gain (Loss) on Sale of Investments | 251.15 | -2.76 | - | 48.48 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -17.17 | -3.7 | -6.05 | -3.23 | -10.81 | Upgrade
|
| Asset Writedown | -3.3 | -13.47 | -6.23 | -11.07 | - | Upgrade
|
| Pretax Income | 30,209 | 29,373 | 23,323 | 23,836 | 22,936 | Upgrade
|
| Income Tax Expense | 7,144 | 6,160 | 6,296 | 6,122 | 4,805 | Upgrade
|
| Net Income | 23,065 | 23,213 | 17,027 | 17,713 | 18,131 | Upgrade
|
| Net Income to Common | 23,065 | 23,213 | 17,027 | 17,713 | 18,131 | Upgrade
|
| Net Income Growth | -0.64% | 36.33% | -3.87% | -2.30% | -5.79% | Upgrade
|
| Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Change (YoY) | - | - | - | -0.95% | 4.38% | Upgrade
|
| EPS (Basic) | 1474.61 | 1484.07 | 1088.60 | 1132.47 | 1159.17 | Upgrade
|
| EPS (Diluted) | 1474.61 | 1484.00 | 1088.50 | 1132.47 | 1148.00 | Upgrade
|
| EPS Growth | -0.63% | 36.33% | -3.88% | -1.35% | -9.75% | Upgrade
|
| Free Cash Flow | 15,832 | 3,411 | 17,707 | 21,361 | 16,788 | Upgrade
|
| Free Cash Flow Per Share | 1012.16 | 218.06 | 1132.04 | 1365.69 | 1063.18 | Upgrade
|
| Dividend Per Share | 600.000 | 375.000 | 350.000 | 350.000 | 325.000 | Upgrade
|
| Dividend Growth | 60.00% | 7.14% | - | 7.69% | -13.33% | Upgrade
|
| Gross Margin | 62.20% | 67.33% | 68.66% | 70.95% | 71.84% | Upgrade
|
| Operating Margin | 20.71% | 26.06% | 25.21% | 25.51% | 26.83% | Upgrade
|
| Profit Margin | 19.38% | 23.91% | 20.02% | 20.14% | 22.21% | Upgrade
|
| Free Cash Flow Margin | 13.30% | 3.51% | 20.82% | 24.29% | 20.57% | Upgrade
|
| EBITDA | 27,803 | 26,980 | 23,055 | 23,931 | 23,396 | Upgrade
|
| EBITDA Margin | 23.36% | 27.79% | 27.11% | 27.22% | 28.66% | Upgrade
|
| D&A For EBITDA | 3,150 | 1,673 | 1,616 | 1,500 | 1,494 | Upgrade
|
| EBIT | 24,653 | 25,307 | 21,439 | 22,431 | 21,902 | Upgrade
|
| EBIT Margin | 20.71% | 26.06% | 25.21% | 25.51% | 26.83% | Upgrade
|
| Effective Tax Rate | 23.65% | 20.97% | 27.00% | 25.69% | 20.95% | Upgrade
|
| Advertising Expenses | 13,563 | 12,408 | 11,533 | 14,695 | 12,686 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.